201-300

201. Bezzina CR, Rook MB, Wielde AAM. Cardiac sodium channel and inherited arrhthmia syndromes Cardiovascular Res 2001; 49: 257-271.

202. Ackerman MJ, Siu BL, Sturner WQ, et al. Postmortem molecular analysis of SCN5A defects in sudden infant death syndrome. JAMA 200; 286: 2264

　-2269.

203. Wedekind H, Smits JP, Schulze-Bahr E, et al. De novo mutation in the SCN5A gene associated with early onset of sudden infant death. Circulation

　2001; 104: 1158-1164.

204. Priori SG, Napolitano C, Giordano U, et al. Brugada syndrome as a cause of sudden cardiac death in children. Lancet 2000; 355: 808-809.

205. Hedley PL, Jørgensen P, Schlamowitz S, et al. The genetic basis of Brugada syndrome: a mutation update. Hum Mutat 2009; 30: 1256-1266.

206. Swan H, Piippo K, Viitasalo M, et al. Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in

　structurally normal hearts. J Am Coll Cardiol 1999; 34: 2035-2042.

207. Tiso N, Stephan DA, Nava A, et al. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right

　ventricular cardiomyopathy type 2 (ARVD2). Hum Mol Genet 2001; 10: 189-194.

208. Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular

　tachycardia. Circulation 2001; 103: 196-200.

209. Laitinen PJ, Brown KM, Piippo K, et al. Mutations of the cardiac Ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia.

　Circulation 2001; 103: 485-490.

210. Aizawa Y, Ueda K, Komura S, et al. A novel mutastion in FKBP12.6 binding regioin of the human cardiac ryanodine receptor gene (R2401H) in a

　Japanese patient with catechlaminergic polumorphic ventricular tachycardia. Int J Cardiol 2005; 99: 343-345.

211. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular

　achycardia. Circulation 2002; 106: 69-74.

212. Bauce B, Rampazzo A, Basso C, et al. Screening for ryanodine receptor type 2 mutations in families with effortinduced polymorphic ventricular

　arrythmias and sudden death. J Am Coll Cardiol 2002; 40: 341-349.

213. Marks AR. Clinical Implications of cardiac ryanodine receptor/calcium release channel mutations linked to sudden cardiac death Circulation 2002;

　106; 8-10.

214. Wehrens XHT, et al. FKBP12.6 deficiency and defective calcium release channel (Ryanodine receptor) fundtion linked to exercise-induced sudden

　cardiac death. Cell 2003; 113: 829-840.

215. George CH, Higgs GV, Lai A. Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediated increased calcium

　erlease in stimulatied cardiomyocytes. Cir Res 2003; 93: 531-540.

216. Postma AV, Denjoy I, Hoorntje TM, et al. Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia.

　Circ Res 2002; 91: e21.

217. Lahat H, Eldar M, Levy-Nissenbaum E, et al. Autosomal recessive catecholamine- or exercise-induced polymorphic ventricular tachycardia: clinical

　features and assignment of the disease gene to chromosome 1p13-21. Circulation 2001; 103: 2822-2827.

218. Borggrefe M, Wolpert C, Antzelevitch C, et al. Short QT syndrome ; Genotype-phenotype correlations. J Electrocardiol 2005; 38: 75-80.

219. Gussak I, Brugada P, Brugada J, et al. Idiopathic short QT interval; a new clinical syndrome? Cardiology 2000; 94: 99-102.

220. Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome; a familial cause of sudden death. Circulation 2003; 108: 965-970.

221. Giustetto C, Di Monte F, Wolpert C, et al. Short QT syndrome ; clinical findings and diagnostic-therapeutic implications. Eur Heart J 2006; 27: 2440

　-2447.

222. Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss-offunction mutations in the cardiac calcium channel underlie a new clinical entity characterized

　by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007; 115: 442-449.

223. Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation ; a review. Am J Cardiol 1993; 72: 23B-5B.

224. Luo S, Tompkins WJ. Parameter evaluation of the inverse power-law spectrum of heart rate; a quantitative approach for ECG arrhythmia evaluation. J

　Electrocardiol 1994; 27: 46-52.

225. Viskin S, Zeltser D, Ish-Shalom M, et al. Is idiopathic ventricular fibrillation a short QT syndrome ? Comparison of QT intervals of patients with

　idiopathic ventricular fibrillation and healthy controls. Heart Rhythm 2004; 1: 587-591.

226. Vincent GM, Timothy KW, Leppert M, et al. The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N Eng J

　Med 1992; 327: 846-852.

227. Brugada R, Hong K, Dumaine R, et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 2004; 109: 30-35.

228. Bellocq C, van Ginneken ACG, Bezzina CR, et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation 2004; 109:

　2394-2397.

229. Priori SG, Pandit SV, Rivolta I, et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Cir Res 2005; 96: 800

　-807.

230. Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia

　Devices: Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/

　AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines) Circulation 2002; 106: 2145-2161.

231. Ruskin JN, DiMarco JP, Garan H. Out-of-hospital cardiac arrest: Electrophysiologic observations and selection of longterm

　antiarrhythmic therapy. N Engl J Med 1980; 303: 607.

232. Roy D, Waxman HL, Kienzle MG, et al. characteristics and long-term follow-up in 119 survivors of cardiac arrest: relation to inducibility at

　electrophysiologic testing. Am J Cardiol 1983; 52: 969-974.

233. Benditt DG, Benson DW Jr, Klein GJ, et al. Prevention of recurrent sudden cardiac arrest: role of provocative electropharmacologic testing. J Am Coll

　Cardiol 1983; 2: 418-425.

234. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators: A comparison of antiarrhythmic-drug therapy with implantable defibrillators

　in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337: 1576-1583.

235. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): A randomized trial of the implantable cardioverter defibrillator

　against amiodarone. Circulation 2000; 101: 1297-1302.

236. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated

　from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102: 748-754.

237. Aizawa Y, Niwano S, Chinushi M, et al. Incidence and mechanism of interruption of reentrant ventricular tachycardia with rapid ventricular pacing.

Circulation 1992; 85: 589-595.

238. Skale BT, Miles WM, Heger JJ, et al. Survivors of cardiac arrest: prevention of recurrence by drug therapy as predicted by electrophysiologic testing

　or electrocardiographic monitoring. Am J Cardiol. 1986; 57: 113-119.

239. Wilber DJ, Garan H, Finkelstein D, et al. Out-of-hospital cardiac arrest. Use of electrophysiologic testing in the prediction of long-term outcome. N

　Engl J Med 1988; 318: 19-24.

240. Glikson M, Lipchenca I, Viskin S, et al. Long-term outcome of patients who received implantable cardioverter defibrillators for stable ventricular

　tachycardia. J Cardiovasc Electrophysiol 2004; 15: 658-664.

241. ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Executive

　summary-. Circulation 2006; 114: 108-1132.

242. 循環器病の診断と治療に関するガイドライン．不整脈薬物治療に関するガイドライン（2009年改訂版）．http://www.j-circ.or.jp/guideline/pdf/JCS2009　

　_kodama_h.pdf（2010年6月閲覧）．

243. Gorgels AP, van de Dool A, Hofs A, et al. Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia.

　Am J Cardiol 1996; 78: 43-46.

244. Komura S, Chinushi M, Furushima H, et al. Efficacy of Procainamide and Lidocaine in Terminating Sustained Monomorphic Ventricular Tachycardia:

　a Retrospective Case Series. Circ J 2010; 74: 864-869.

245. Israel CW, Barold S. Review Article. Electrical storm in patients with an implanted defibrillator: a matter of definition. A.N.E. 2007; 12: 375-382.

246. Nademenee K, Taylor R, Bailey WE, et al. Treating electrical storm. Sympathetic block versus advanced cardiac life support guided therapy.

　Circulation 2000; 102: 742-747.

247. Schreieck J, Zrenner B, Deisenhofer I, et al. Rescue ablation of electrical storm in patients with ischemic cardiomyopathy: a potential-guided ablation

　approach by modifying substrate of intractable, unmappable ventricular tachycardias. Heart Rhythm 2005; 2: 10-14.

248. Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable

　Cardioverter-Defibrillator Study Group. N Engl J Med 1999; 340: 1855-1862.

249. Watanabe H, Chinushi M, Washizuak T, et al . Electrophysiologic study guided theerapy with sotalol for lifethreatening ventricualr

　tachyarrhythmias. PACE 2005; 28: 285-290.

250. Connolly SJ, Dorian P, Roberts RS, et al. Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators. Comparison of

　beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a

　randomized trial. JAMA 2006; 295: 165-171.

251. Rubenstein JJ, Schulman CL,Yurchak PM, et al. Clinical spectrum of the sick sinus syndrome.Circulation 1972; 46: 5-13.

252. Sutton R, Kenny RA. The natural history of sick sinus syndrome. PACE 1986; 9: 1110-1114.

253. Shaw DB, Holman RR, Gowers JI. Survival in sinoatial disorder (sick-sinus syndrome). Br Med J 1980; 280: 139-141.

254. Dhingra RC, Denes P, Wu D, et al. The significance of second degree atriovetnricular block and bundle branch block: Observations regarding ste and

　type or block. Circualtion 1974; 49: 638-646.

255. Shaw DB, Kekwich CA, Veale D, et al. Survival in second degree satrioventricular block. Br Heart J 1985 ;53: 587-593.

256. Johansson BW. Completed heart block. A clinical hemodynamic and pharmacological study in patients with and without an artificial pacemaker.Acta

　Med Scand 1966; 180 (Suppl 451): 1-127.

257. Ginks W, Leatham A, Siddons H. Prognosis of patients paced for chronic atrioventricular block.Br Heart J 1979; 41: 633-636.

258. Shen WK, Hammill SC, Hayes DL, et al. Long-term survival after pacemaker implantation for heart block in patients 65 years. Am J Cardiol 1984; 74:

　560-564.

259. Schneider JF, et al. Comparative features of newly acquired left and right bundle branch block in the sgeneral population: the Framingham study. Am

　J Cardiol 1981; 47: 931-940.

260. Baldasseroni S, et al. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with

　congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J 2002; 143: 398-405.

261. McAnulty JH, et al. Natural history of “high-grade” bundle-branch block: final report of a prospective study. N Eng J Med 1982; 307: 137-143.

262. Rowe JC, White PD. Complete heart block: a follow-up study. Ann Intern Med 1958; 49: 260-270.

263. Michaelsson M, Jonzon A, Riesenfeld T. Isolated congenital complete atrioventricular block in adult life. Circulation 1995; 92: 442-449.

264. Camm AJ, Lau CP. Syncope of undetermined origin: diagnosis and management. Prog Cardiol 1988; 1: 139-156.

265. Middlelkauff HR, Stevenson WG, Saxon LA. Syncope in advanced heart failure: High sudden death risk regardless of syncope etiology. J Am Coll

　Cardiol 1993; 21: 110-116.

266. Benditt DG, Goldstein MA, Adler S, et al. Neurally mediated syncopal syndromes:pathophysiology and clinical evaliation. In: Mandel WJ,ed. Cardiac

　arrhythmias 3rd edn.JB Lippincott, 1995: 879-906.

267. Johnson AM. Aortic stenosis,sudden death, and the left ventricular baroreceptors.Br heart J 1971; 33: 1-5.

268. Pitt B. Sudden cardiac death: Role of left ventricular dysfunction. Ann N Y Acad Sci 1982; 382: 218-222.

269. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J

　Med 1991; 325: 293-302.

270. Goldman S, Johnson G, Cohn JN, et al. Mechanism of death in heart failure. The Vasodilator-Heart Failure Trials. The V-HeFT VA Cooperative

　Studies Group. Circulation 1993; 87: Ⅵ 24-31.

271. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de estudio de la sobrevida

　en la insuficiencia cardiaca en argentina (GESICA). Lancet 1994; 344: 493-449.

272. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival trial

　of antiarrhythmic therapy in congestive heart failure. N Engl J Med 1995; 333: 77-82.

273. CIBIS-II investigators and committees. The Cardiac insufficiency Bisoprolol Study II (CIBIS-II) -a randomized trial. Lancet 1999; 353: 9-13.

274. Kjekshus J. Arrhythmia and mortality in congesitve heart failure. Am J Cardiol 1990; 65: 42-48I.

275. Marchlinski FE, Buxton AE, Waxman HL, et al. Identifying patients at risk of sudden death after myocardial infarction: Value of the response to

　programmed stimulation, degree of ventricular ectopic activity and severity of left ventricular dysfunction. Am J Cardiol 1983; 52: 1190-1196.

276. Olson HG, Lyons KP, Troop P, et al. The high-risk acute myocardial infarction patient at 1-year follow-up: identification at hospital discharge by

　ambulatory electrocardiography and radionuclide ventriculography. Am Heart J 1984; 107: 358-366.

277. Bailey JJ, Berson AS, Handelsman H, et al. Utility of current risk stratification tests for predicting major arrhythmic events after myocardial infarction.

　J Am Coll Cardiol 2001; 38: 1902-1911.

278. Popovic AD, Neskovic AN, Pavlovski K, et al. Association of ventricular arrhythmias with left ventricular remodelling after myocardial infarction. Heart

　1997; 77: 423-427.

279. Usuku H, Nakayama M, Sumida H, et al. Pump failure death and sudden cardiac death in patients with cardiac dysfunction: A search for prognostic

　predictive factors-A long-term follow-up study. J Cardiol. 2010; 55: 55-64.

280. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillation in patients with myocardial infarction and reduced ejection fraction.

　N Engl J Med 2002; 346: 877-883.

281. Kadish A and Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in

　patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350: 2151-2158.

282. Bardy GH, Lee KL, Mark DB et al. Amiodarone or implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352;225-237.

283. Teerlink JR, Jalaluddin M, Anderson S, et al. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased

　risk of suddendeath. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. Circulation 2000; 101: 40-46.

284. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure : Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart

　Failure（MERIT-HF）. Lancet 353: 2001-2007.

285. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart

　failure. (V-HeFT II). N Engl J Med 1991; 325: 303-310.

286. Pfeffer M, Braunwald E., Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial

　infarction. N Engl J Med 1992; 327: 669-677.

287. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting- enzyme inhibitor trandolapril in patients with left ventricular

　dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333: 1670-1676.

288. Pitt B., et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE).

　Lancet 1997; 349: 747-752.

289. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized

　Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.

290. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845-1853.

291. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352:

　1539-1549.

292. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N

　Engl J Med 2001; 344: 873-880.

293. Bristow MR, Saxon LA, Boehmer J, et al. for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION)

　Investigators. Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350:

　2140-2150.

294. Tofler GH, Stone PH, Muller JE, et al. Prognosis after cardiac arrest due to ventricular tachycardia or ventricular fibrillation associated with acute

　myocardial infarction (the MILIS Study). Multicenter Investigation of the Limitation of Infarct Size. Am J Cardiol 1987; 60: 755-761.

295. Volpi A, Maggioni A, Franzosi MG, et al. In hospital prognosis of patients with acute myocardial infarction complicated by primary ventricular

　fibrillation. N Engl J Med 1987; 317: 257-261.

296. Behar S, Coldbourt U, Reicher-Reiss H, et al. Prognosis of acute myocardial infarction complicated by primary ventricular fibrillation. Principal

　Investigators of the SPRINT Study. Am J Cardiol 1990; 66: 1208-1211.

297. Volpi A, Cavalli A, Franzosi MG, et al. One-year prognosis of primary ventricular fibrillation complicating acute myocardial infarction. The GISSI

　(Gruppo Italiano per lo Study della Streptochinasi nell’ Infarto miocardico) investigators. Am J Cardiol 1989; 63: 1174-1178.

298. Goldberg RJ, Yarzebski J, Spencer FA, et al. Thirty-year trends (1975-2005) in the magnitude, patient characteristics, and hospital outcomes of

　patients with acute myocardial infarction complicated by ventricular fibrillation. Am J Cardiol 2008; 102: 1595-1601.

299. O’Doherty M, Tayler DI, Quinn E, et al. Five hundred patients with myocardial infarction monitored within one hour of symptoms. Br Med J 1983; 286:

　1405-1408.

300. Mehta RH, Starr AZ, Lopes RD, et al; APEX AMI Investigators. Incidence of and outcomes associated with ventricular tachycardia or fibrillation in

　patients undergoing primary percutaneous coronary intervention. JAMA 2009; 301: 1779-1789.

文献